Workflow
CRISPR/Cas9
icon
Search documents
Editas Medicine Announces U.S. Court of Appeals for the Federal Circuit Remands CRISPR Patent Interference to Patent Trial and Appeal Board
GlobeNewswire News Room· 2025-05-12 20:01
Core Viewpoint - Editas Medicine, Inc. announced a partial affirmation and partial vacate of a previous decision by the U.S. Court of Appeals regarding patent interference related to CRISPR/Cas9 editing, with the case remanded back to the Patent Trial and Appeal Board (PTAB) for further review [1] Group 1: Legal and Patent Developments - The U.S. Court of Appeals for the Federal Circuit has affirmed-in-part and vacated-in-part the PTAB's decision regarding patents for CRISPR/Cas9 editing in human cells involving the University of California, University of Vienna, Emmanuelle Charpentier, and the Broad Institute [1] - Editas Medicine's in-licensed patents covering CRISPR/Cas12a are not affected by this decision and are not involved in the ongoing interference proceedings [1] Group 2: Company Strategy and Intellectual Property - The company remains confident in the strength of its intellectual property (IP) portfolio, which is expected to generate significant value now and in the future [2] - Editas holds a large portfolio of foundational U.S. and international patents, including exclusive licenses for Cas9 and Cas12a patent estates, which are crucial for developing human medicines [2] - The foundational IP includes issued patents covering fundamental aspects of CRISPR/Cas12a and CRISPR/Cas9 gene editing in all human cells, essential for CRISPR-based medicines [2] Group 3: Company Mission and Focus - Editas Medicine is focused on translating the potential of CRISPR/Cas12a and CRISPR/Cas9 systems into a pipeline of in vivo medicines for serious diseases [3] - The company aims to discover, develop, manufacture, and commercialize transformative gene editing medicines for a broad class of diseases [3]
基因编辑治疗晚期胃肠道癌显成效
Ke Ji Ri Bao· 2025-05-06 23:27
(文章来源:科技日报) 新疗法通过CRISPR/Cas9技术对肿瘤浸润淋巴细胞(TIL)进行基因改造。结果显示,这些经过"武 装"的免疫细胞会使一种CISH基因失活,从而更精准地识别和攻击癌细胞。 在针对12名晚期转移性患者的临床试验中,该疗法展现出良好的安全性,未出现严重不良反应。更令人 振奋的是,部分患者病情得到有效控制,其中一位患者的转移瘤在数月后完全消失,并保持两年无复 发。 研究团队认为,最新研究表明,CISH基因可能是阻碍T细胞识别肿瘤的关键。与传统需要反复给药的癌 症疗法不同,新基因编辑疗法通过一次性改造T细胞就能实现持久效果。 研究团队成功培育并输注了超过100亿个工程TIL细胞,不仅验证了大规模临床级细胞制备的可行性, 更有可能开创癌症免疫治疗的新范式。不过,他们也坦承,虽然初步结果令人鼓舞,但现有工艺仍面临 成本高、流程复杂等挑战。他们计划着力优化治疗方案,深入探究疗效差异机制,为更多患者带来福 音。 美国明尼苏达大学科研团队在最新一期《柳叶刀·肿瘤学》杂志发表论文称,全球首例运用CRISPR/Cas9 基因编辑技术治疗晚期胃肠道癌的人体临床试验取得阶段性成功,证实了该疗法的安全性和潜在疗 ...
Editas Medicine to Announce First Quarter 2025 Financial Results and to Participate in Investor Conference in May
GlobeNewswire News Room· 2025-05-05 20:01
CAMBRIDGE, Mass., May 05, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced that it plans to announce Q1 2025 financial results and business updates on May 12 via press release and SEC filings. As previously announced, the Company does not plan to host quarterly financial results conference calls moving forward. Additionally, Editas Medicine management will participate in the f ...